Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver

被引:0
|
作者
Kerr, T [1 ]
Palepu, A
Barnes, G
Walsh, J
Hogg, R
Montaner, J
Tyndall, M
Wood, E
机构
[1] Canadian HIV AIDS Legal Network, Montreal, PQ, Canada
[2] St Pauls Hosp, Brit Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada
[3] St Pauls Hosp, Ctr Hlth Evaluat & Outcomes Sci, Vancouver, BC V6Z 1Y6, Canada
[4] Univ British Columbia, Dept Med, Vancouver, BC V5Z 1M9, Canada
[5] Univ Victoria, Dept Human & Social Dev, Victoria, BC, Canada
[6] Univ Victoria, Dept Educ Psychol & Leadership Studies, Victoria, BC, Canada
[7] Univ British Columbia, Dept Healthcare & Epidemiol, Vancouver, BC V5Z 1M9, Canada
关键词
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Sub-optimal adherence to highly active antiretroviral therapy (HAART) among injection drug users (IDUs) is a significant concern. As such, there is an urgent need to identify psychosocial determinants of adherence that can be incorporated into interventions designed to promote optimal adherence. Objective: To identify psychosocial determinants of adherence to HAART, as well as self-reported reasons for missing doses of HAART among HIV-infected IDUs. Methods: We developed an eight-item adherence self-efficacy scale 'comprised of two sub-scales: adherence efficacy and self-regulatory efficacy. We examined correlates between adherence self-efficacy, outcome expectations, socio-demographic characteristics, drug use and risk behaviours, social support and HAART adherence among 108 HIV-infected participants in the Vancouver Injection Drug Users Study (VIDUS). Pharmacy-based adherence to HAART was obtained through a confidential record linkage to the province of British Columbia's HIV/AIDS Drug Treatment Program. Participants were defined as adherent if they picked-up 95% of their HAART prescriptions. Participants were also asked to indicate reasons for missing doses of HAART. Logistic regression was used to identify the factors independently associated with adherence to HAART. Results: Seventy-one (66%) HIV-infected IDUs were less than 95% adherent. Forgetting was the most frequently cited reason (27%) for missing doses of HAART. Factors independently associated with adherence to HAART included adherence efficacy expectations [OR=1.8 (95% CI: 1.0-3.1); P=0.039] and negative outcome expectations [OR=0.8 (95% CI: 0.7-0.9); P=0.027]. Conclusions: We found low rates of adherence to HAART among IDUs. Psychological constructs derived from self-efficacy theory are highly germane to the understanding of adherence behaviour, and interventions that address these constructs should be developed and tested among HIV-infected drug users.
引用
收藏
页码:407 / 414
页数:8
相关论文
共 50 条
  • [1] Adherence and antiretroviral therapy in injection drug users
    Sherer, R
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (06): : 567 - 568
  • [2] Highly active antiretroviral therapy for injection drug users: physician-recommended strategies for enhanced adherence
    Vassilev, ZP
    Hagan, H
    [J]. ANTIVIRAL THERAPY, 2004, 9 (03) : 461 - 461
  • [3] Time to initiating highly active antiretroviral therapy among HIV infected injection drug users
    Celentano, DD
    Galai, N
    Sethi, AK
    Shah, NG
    Strathdee, SA
    Vlahov, D
    Gallant, JE
    [J]. AIDS, 2001, 15 (13) : 1707 - 1715
  • [4] Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users
    Wood, E
    Montaner, JSG
    Yip, B
    Tyndall, MW
    Schechter, MT
    O'Shaughnessy, MV
    Hogg, RS
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2003, 169 (07) : 656 - 661
  • [5] Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting
    Krusi, Andrea
    Milloy, M-J
    Kerr, Thomas
    Zhang, Ruth
    Guillemi, Silvia
    Hogg, Robert
    Montaner, Julio
    Wood, Evan
    [J]. ANTIVIRAL THERAPY, 2010, 15 (05) : 789 - 796
  • [6] Mortality among urban drug users and the impact of highly active antiretroviral therapy
    Celentano, DD
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 41 (06) : 873 - 874
  • [7] Improvement of anemia among HIV-infected injection drug users receiving highly active antiretroviral therapy
    Semba, RD
    Shah, N
    Vlahov, D
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 26 (04) : 315 - 319
  • [8] Sexual Risk Behavior Among Injection Drug Users Before Widespread Availability of Highly Active Antiretroviral Therapy
    Melanie L. Rusch
    Homayoon Farzadegan
    Patrick M. Tarwater
    Mahboobeh Safaeian
    David Vlahov
    Steffanie A. Strathdee
    [J]. AIDS and Behavior, 2005, 9 : 289 - 299
  • [9] Sexual risk behavior among injection drug users before widespread availability of highly active antiretroviral therapy
    Rusch, ML
    Farzadegan, H
    Tarwater, P
    Safaeian, M
    Vlahov, D
    Strathdee, SA
    [J]. AIDS AND BEHAVIOR, 2005, 9 (03) : 289 - 299
  • [10] Highly active antiretroviral therapy and survival in HIV-Infected injection drug users
    Wood, Evan
    Hogg, Robert S.
    Lima, Viviane Dias
    Kerr, Thomas
    Yip, Benita
    Marshall, Brandon D. L.
    Montaner, Julio S. G.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (05): : 550 - 554